Results 61 to 70 of about 775,670 (354)

Design, synthesis and in vitro biological evaluation of quinazolinone derivatives as EGFR inhibitors for antitumor treatment

Journal of Enzyme Inhibition and Medicinal Chemistry, 2020
In this paper, a series of novel 3-methyl-quinazolinone derivatives was designed, synthesised and evaluated for antitumor activity in vitro on wild type epidermal growth factor receptor tyrosine kinase (EGFRwt-TK) and three human cancer cell lines ...
Yi Le, Yiyuan Gan, Yihong Fu, Jiamin Liu, Wen Li, Xue Zou, Zhixu Zhou, Zhenchao Wang, Guiping Ouyang, Longjia Yan   +9 more
doaj   +1 more source

GENETIC POLYMORPHISM OF RETROPERITONEAL MYXOID LIPOSARCOMA

Сибирский онкологический журнал, 2020
Objective: to detect new molecular genetic markers and therapeutic targets in retroperitoneal myxoid liposarcoma.Material and Methods. DNA samples isolated from tumor tissue and obtained from formalinfixed paraffin-embedded (FFPE) slides were used.
A. Yu. Volkov, V. M. Safronova, S. N. Nered, L. N. Lyubchenko, I. S. Stilidi   +4 more
doaj   +1 more source

Role of predictable biomarkers in early detection of cardiovascular events in Chronic Kidney Disease III and IV

Current Issues in Pharmacy and Medical Sciences, 2022
This comes about because of a lack of predicted biomarkers in the risk analysis of CVD events in chronic kidney disease (CKD) patients. The present study aimed to determine the clinical utility of independent, predictable biomarkers such as serum ...
Durgaprasad Bhamidipaty Kanaka, Malla Rama Rao, Lahari Bhamidipaty Durgananda, Vijayalakshmi Payala, Guntoory Indira, Kalyan Kolli Viswa   +5 more
doaj   +1 more source

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács, Zoltán Köllő, Balázs Gellért Karvaly, Mahmoud Obeidat, Rita Nagy, Péter Hegyi, Brigitta Teutsch, Eszter Tuboly, Miklós Garami   +8 more
wiley   +1 more source

The impact of weekly semaglutide, a glucagon-like peptide-1 agonist, on kidney outcomes in adults with type 2 diabetes mellitus

Journal of Family Medicine and Primary Care
Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder associated with kidney complications. This study aims to investigate the effects of weekly subcutaneous semaglutide, a GLP-1 agonist, on kidney outcomes.
Ahmad A Algarni, Fahad S Alqarni, Hanin A Shalaby   +2 more
doaj   +1 more source

Blockade of the P2Y2 Receptor Attenuates Alcoholic Liver Inflammation by Targeting the EGFR-ERK1/2 Signaling Pathway

Drug Design, Development and Therapy, 2022
Zhen-Ni Liu,1– 3,* Qian-Qian Su,4,* Yu-Hui Wang,1– 3,* Xue Wu,1– 3 Xiong-Wen Lv1– 3 1Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University ...
Liu ZN, Su QQ, Wang YH, Wu X, Lv XW
doaj  

Correlation of sonographic parameters with renal function in patients with newly diagnosed chronic kidney disease

Journal of Ultrasonography, 2022
To correlate sonographic renal parameters (mean renal cortical thickness, length and volume) with renal functions in patients with newly diagnosed chronic kidney disease.
Garg Aborishi, Jhobta Anupam, Kapila Sumala, Rathour Devesha   +3 more
doaj   +1 more source

Fluctuations of estimated glomerular filtration rate outside kidney disease improving global outcomes diagnostic criteria for acute kidney injury in end-stage liver disease outpatients and outcome postliver transplantation [PDF]

, 2017
Background. Renal dysfunction in end-stage liver disease (ESLD) results fromsystemic conditions that affect both liver and kidney with activation of vasoconstrictor systems.
Berloco, Pasquale Bartolomeo, Cappoli, Andrea, Fiacco, Federica, GINANNI CORRADINI, Stefano, Melandro, Fabio, Merli, Manuela, Mitterhofer, Anna Paola, Nofroni, Italo, Poli, Edoardo, Rossi, Massimo, Tinti, Francesca, Umbro, Ilaria, Zavatto, Assunta   +12 more
core   +1 more source

Perspectives on Drug Product Design Among Patients with Lung Cancer in the United Kingdom

Pulmonary Therapy
Introduction The use of oral anticancer medications has become more prevalent in cancer therapy. This is particularly the case in the management of advanced non-small cell lung cancer (NSCLC).
Joshua R. Coulter, Louis Edward Baig, Amy Antipas, Debra Montague, Angela Terry, Sally-Anne Dews, Michaela Ogden-Barker, Colm Doody, Brett Hauber   +8 more
doaj   +1 more source

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation

Медицинский совет, 2019
In the open prospective non-randomized single-center study we recruited patients with advanced NSCLC harboring EGFR mutations. Initially there were two months of treatment by gefitinib 250 mg daily.
K. K. Laktionov, D. I. Yudin, V. V. Breder, E. V. Reutova, K. P. Laktionov, D. T. Marinov, D. A. Peregudov, M. S. Ardzinba   +7 more
doaj   +1 more source